Literature DB >> 25774476

Redefining dose-limiting toxicity.

Sophie Postel-Vinay1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25774476

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  4 in total

1.  Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.

Authors:  Jean-Marie Michot; Lina Benajiba; Laura Faivre; Capucine Baldini; Lelia Haddag; Clement Bonnet; Christophe Massard; Frederic Bigot; Camille Bigenwald; Benjamin Verret; Zoé A P Thomas; Andrea Varga; Anas Gazzah; Antoine Hollebecque; David Ghez; Julien Lazarovici; Rastilav Balheda; Aurore Jeanson; Sophie Postel-Vinay; Alina Danu; Jean-Charles Soria; Xavier Paoletti; Vincent Ribrag
Journal:  Invest New Drugs       Date:  2017-06-09       Impact factor: 3.850

Review 2.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

Review 3.  Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways.

Authors:  J Russell Hoverman
Journal:  Cancer Med       Date:  2020-06-10       Impact factor: 4.452

4.  Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.

Authors:  Revathi Ananthakrishnan; Stephanie Green; Mark Chang; Gheorghe Doros; Joseph Massaro; Michael LaValley
Journal:  Contemp Clin Trials Commun       Date:  2016-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.